Literature DB >> 8861696

Primary central nervous system lymphoma: variety of clinical manifestations and survival.

D G Kim1, D H Nam, H W Jung, K S Choi, D H Han.   

Abstract

A retrospective analysis of 23 non-immune compromised patients with primary central nervous system lymphoma (PCNSL) is reported. The patients consist of 14 males and 9 females and the median age is 50 years. Most patients presented with focal neurological deficits or symptoms of increased intracranial pressure (ICP) due to mass effects around the periventricular area. However, there were four cases of diffuse type, one case of intramedullary tumour, and four cases with rapid disease progression. All the patients underwent histological confirmation by craniotomy (16 cases) or stereotactic biopsy (7 cases). The radiation therapy started after histological diagnosis in all and 6 cases received additional chemotherapy. The median survival after diagnosis of overall patients was 23 months. Six patients are in disease free status at a mean of 35 months follow-up. The uni- and multi-variative risk analysis revealed five favourable factors on survival: (1) age less than 60 years (0.05 < p < 0.1); (2)pre-operative Karnofsky performance scale (KPS) > or = 70 (p < 0.05); (3) symptom duration over four weeks (p < 0.05); (4) radiation dosage > or = 5500 cGy (p < 0.05); (5)absence of malignant cells in cerebrospinal fluid (CSF) (p < 0.05). The most frequent site of recurrence was the local area as shown in seven cases out of 11 recurrent cases. But six patients had diffuse recurrence (4 cases), systemic recurrence (2 cases), and drop metastasis (1 case). Although the recurred PCNSL had rapid progression and a grave prognosis, aggressive treatment prolonged the postrecurrence survival time significantly. Our experience suggests that 1) there are various clinical and radiological presentations and progressions of the disease; 2) treatment method should be decided along with the clinical presentation, progression of disease, and prognostic factors; 3) early diagnosis and early detection of recurrence enable the start of definitive treatment when the medical condition is still satisfactory.

Entities:  

Mesh:

Year:  1996        PMID: 8861696     DOI: 10.1007/bf01411738

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  34 in total

1.  Primary malignant lymphomas of the central nervous system.

Authors:  J M Henry; R R Heffner; S H Dillard; K M Earle; R L Davis
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

2.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

3.  Radiation therapy in the management of primary malignant lymphoma of the brain.

Authors:  M P Berry; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-01       Impact factor: 7.038

4.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

5.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

Review 6.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

7.  Primary central nervous system lymphoma: a role for adjuvant chemotherapy.

Authors:  M C Chamberlain; V A Levin
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

8.  Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy.

Authors:  J R Crossen; D L Goldman; S A Dahlborg; E A Neuwelt
Journal:  Neurosurgery       Date:  1992-01       Impact factor: 4.654

9.  Primary lymphoma of the central nervous system.

Authors:  L Letendre; P M Banks; D F Reese; R H Miller; P W Scanlon; J M Kiely
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

10.  Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series.

Authors:  E A Neuwelt; E P Frenkel; M K Gumerlock; R Braziel; B Dana; S A Hill
Journal:  Cancer       Date:  1986-10-15       Impact factor: 6.860

View more
  3 in total

1.  Brain lymphoma: usefulness of the magnetic resonance spectroscopy.

Authors:  Sophie Taillibert; Rémy Guillevin; Carole Menuel; Marc Sanson; Khê Hoang-Xuan; Jacques Chiras; Hugues Duffau
Journal:  J Neurooncol       Date:  2007-09-04       Impact factor: 4.130

Review 2.  Intramedullary lesions of the conus medullaris: differential diagnosis and surgical management.

Authors:  Florian H Ebner; Florian Roser; Marcus A Acioly; Wolfgang Schoeber; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2008-09-27       Impact factor: 3.042

3.  Primary Non-Hodgkin's Lymphoma of the Spine: A Case Report and Literature Review.

Authors:  Elias Moussaly; Bassel Nazha; Mazen Zaarour; Jean Paul Atallah
Journal:  World J Oncol       Date:  2015-10-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.